The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127594021 12759402 1 I 20140808 20160907 20160919 20160919 EXP FR-HQ SPECIALTY-FR-2016INT000878 INTERCHEM SASSIER M, PEYRO-SAINT-PAUL L, CLARISSE B, LECONTE A, COQUEREL A, ALEXANDRE J, ET AL.. CHEMOTHERAPY (PLATINUM AND PEMETREXED) IN COMBINATION WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER INDUCES MAJOR GASTROINTESTINAL TOXICITY. J CLIN PHARM THER. 2016;41 (4):447-448 56.00 YR F Y 0.00000 20160919 PH FR FR

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127594021 12759402 1 PS CISPLATIN. CISPLATIN 1 90 MG, EVERY 3 WEEKS, [3 CYCLES] D 18057 90 MG
127594021 12759402 2 SS CISPLATIN. CISPLATIN 1 D 18057
127594021 12759402 3 SS CISPLATIN. CISPLATIN 1 D 18057
127594021 12759402 4 SS PEMETREXED PEMETREXED 1 600 MG, EVERY 3 WEEKS, [3 CYCLES] D 0 600 MG
127594021 12759402 5 SS PEMETREXED PEMETREXED 1 D 0
127594021 12759402 6 SS PEMETREXED PEMETREXED 1 D 0
127594021 12759402 7 SS ERLOTINIB ERLOTINIB 1 150 MG, QD D 0 150 MG
127594021 12759402 8 SS ERLOTINIB ERLOTINIB 1 Unknown UNK D 0
127594021 12759402 9 SS ERLOTINIB ERLOTINIB 1 D 0
127594021 12759402 10 SS APREPITANT. APREPITANT 1 UNK U 0
127594021 12759402 11 SS VERAPAMIL VERAPAMIL HYDROCHLORIDE 1 UNK U 0
127594021 12759402 12 C PREDNISOLONE. PREDNISOLONE 1 UNK U 0
127594021 12759402 13 C ONDANSETRON ONDANSETRON 1 UNK U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127594021 12759402 1 Non-small cell lung cancer metastatic
127594021 12759402 2 Metastases to central nervous system
127594021 12759402 3 Disease progression
127594021 12759402 4 Non-small cell lung cancer metastatic
127594021 12759402 5 Metastases to central nervous system
127594021 12759402 6 Disease progression
127594021 12759402 7 Non-small cell lung cancer metastatic
127594021 12759402 8 Metastases to central nervous system
127594021 12759402 9 Disease progression
127594021 12759402 10 Antiemetic supportive care
127594021 12759402 11 Hypertension
127594021 12759402 12 Antiemetic supportive care
127594021 12759402 13 Antiemetic supportive care

Outcome of event

Event ID CASEID OUTC COD
127594021 12759402 LT
127594021 12759402 OT
127594021 12759402 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
127594021 12759402 Asthenia
127594021 12759402 Diarrhoea
127594021 12759402 Drug interaction
127594021 12759402 Nausea
127594021 12759402 Renal failure
127594021 12759402 Vomiting

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127594021 12759402 1 20140806 0
127594021 12759402 4 20140806 0
127594021 12759402 7 201402 0
127594021 12759402 8 20140806 0